Year Founded
2022
Ownership
Private
Employees
~50
Therapeutic Areas
Pulmonology
Stage
Phase 3
Modalities
Small molecule

Areteia Therapeutics General Information

Dexpramipexole, a first-in-class oral eosinophil maturation inhibitor, has shown significant eosinophil-lowering efficacy and tolerability in Phase II trials and is currently in Phase III development for eosinophilic asthma.

Contact Information

Website
Primary Industry
[ "Pharma", "Biotech" ]
Corporate Office
Chapel Hill, North Carolina
United States

Drug Pipeline

dexpramipexole
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Areteia Therapeutics's pipeline data

Book a demo

Key Partnerships

Population Health Partners, Knopp Biosciences, Validae Health

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Areteia Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCFeb 13, 2024$75.0MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Areteia Therapeutics's complete valuation and funding history, request access »

Areteia Therapeutics Investors

Bain Capital Life Sciences
Investor Type: Venture Capital
Holding: Minority
Access Biotechnology
Investor Type: Venture Capital
Holding: Minority
GV
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 10 investors. Get the full list »